Engineering and characterization of a symbiotic selection-marker-free vector-host system for therapeutic plasmid production

Shi,Xinchang; Wang,Junzhi

doi:10.3892/mmr.2015.3945

Engineering and characterization of a symbiotic selection-marker-free vector-host system for therapeutic plasmid production

Authors:
- Xinchang Shi
- Junzhi Wang
View Affiliations

Affiliations: Department of Biopharmaceutics, School of Pharmacy, Fourth Military Medical University, Xian, Shaanxi 710032, P.R. China
Published online on: June 17, 2015 https://doi.org/10.3892/mmr.2015.3945
Pages: 4669-4677

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to develop a symbiotic selection-marker-free plasmid and host system that would allow successful plasmid maintenance and amplification for use in gene therapy. Initially, the chromosomal aspartate‑semialdehyde dehydrogenase (asd) gene was disrupted in DH10B Escherichia coli using Red recombinase‑mediated homologous recombination. This method required the use of linear DNA fragments carrying kan‑kil genes, and/or homologous extensions to the targeted locus. The resultant auxotrophic cell wall‑deficient strain (DH10BΔasd) was evaluated as a symbiotic host for amplification of the marker‑free plasmid, allowing it to supply ASD activity. In order to construct the plasmid, an asd expression cassette was inserted, under the control of the nirB promoter, into a eukaryotic expression vector, and its kanamycin resistance gene was subsequently removed. The symbiotic plasmid and host system was assessed for numerous plasmid production and stability parameters, including structure, yield, plasmid‑retention rate, and bacterial storability, under various conditions. The presence of the plasmid was subsequently confirmed by growth test, restriction enzyme mapping, and sequencing. The plasmid yield and copy number produced in the symbiotic cells, in the absence of antibiotic selection, were shown to be similar to those produced under kanamycin selection, in the cells containing the precursor plasmid and kanamycin resistance gene. Furthermore, the results of the present study demonstrated that when inoculated with <1% inoculant volume, >98% of the cells in the culture retained the plasmid regardless of the number of passages. The strain was stable when stored at ‑70˚C, with negligible viability loss over 12 months. The constructed plasmid is stable and has potential in future gene therapy, while much work is still required.

View Figures

View References

1	Tolmachov OE: Building mosaics of therapeutic plasmid gene vectors. Current gene therapy. 11:466–478. 2011. View Article : Google Scholar : PubMed/NCBI
2	Nahaei M, Valizadeh H, Baradaran B, et al: Preparation and characterization of chitosan/beta-cyclodextrin nanoparticles containing plasmid DNA encoding interleukin-12. Drug research (Stuttg). 63:7–12. 2013. View Article : Google Scholar
3	Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M and Riviere I: Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine. 25:5013–5024. 2007. View Article : Google Scholar : PubMed/NCBI
4	Norell H, Poschke I, Charo J, et al: Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 8:532010. View Article : Google Scholar : PubMed/NCBI
5	Smith LR, Wloch MK, Ye M, et al: Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 28:2565–2572. 2010. View Article : Google Scholar : PubMed/NCBI
6	Oliveira PH and Mairhofer J: Marker-free plasmids for biotechnological applications - implications and perspectives. Trends Biotechnol. 31:539–547. 2013. View Article : Google Scholar : PubMed/NCBI
7	Pruden A, Pei R, Storteboom H and Carlson KH: Antibiotic resistance genes as emerging contaminants: Studies in northern Colorado. Environ Sci Technol. 40:7445–7450. 2006. View Article : Google Scholar : PubMed/NCBI
8	7.0 EP: Gene transfer medical products for human use. 648, 2011.
9	U.S. Food and Drug Administration: Guidance for human somatic cell therapy and gene therapy. 1998.
10	Vandermeulen G, Marie C, Scherman D and Préat V: New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther. 19:1942–1949. 2011. View Article : Google Scholar : PubMed/NCBI
11	Haziza C, Stragier P and Patte JC: Nucleotide sequence of the asd gene of Escherichia coli: Absence of a typical attenuation signal. EMBO J. 1:379–384. 1982.PubMed/NCBI
12	Narayanan K and Warburton PE: DNA modification and functional delivery into human cells using Escherichia coli DH10B. Nucleic Acids Res. 31:e512003. View Article : Google Scholar : PubMed/NCBI
13	Datsenko KA and Wanner BL: One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA. 97:6640–6645. 2000. View Article : Google Scholar : PubMed/NCBI
14	Curtiss R III, Galan JE, Nakayama K and Kelly SM: Stabilization of recombinant avirulent vaccine strains in vivo. Res Microbiol. 141:797–805. 1990. View Article : Google Scholar : PubMed/NCBI
15	Dong WR, Xiang LX and Shao JZ: Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathway. Appl Environ Microbiol. 76:2295–2303. 2010. View Article : Google Scholar : PubMed/NCBI
16	Durfee T, Nelson R, Baldwin S, et al: The complete genome sequence of Escherichia coli DH10B: Insights into the biology of a laboratory workhorse. J Bacteriol. 190:2597–2606. 2008. View Article : Google Scholar : PubMed/NCBI
17	Grant SG, Jessee J, Bloom FR and Hanahan D: Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc Natl Acad Sci USA. 87:4645–4649. 1990. View Article : Google Scholar : PubMed/NCBI
18	Galán JE, Nakayama K and Curtiss R III: Cloning and characterization of the asd gene of Salmonella typhimurium: Use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene. 94:29–35. 1990. View Article : Google Scholar : PubMed/NCBI
19	Zhao Z, Wang C, Xue Y, et al: Immunogenicity and protective efficacy of pertactin recombinants against Bordetella bronchiseptica challenge. Wei Sheng Wu Xue Bao. 50:1239–1245. 2010.In Chinese. PubMed/NCBI
20	Arias-Lopez C, Lazaro-Trueba I, Kerr P, et al: p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 7:219–224. 2006. View Article : Google Scholar
21	Makoff AJ and Oxer MD: High level heterologous expression in E. coli using mutant forms of the lac promoter. Nucleic Acids Res. 19:2417–2421. 1991. View Article : Google Scholar : PubMed/NCBI
22	Teeter KC, Thibodeau LM, Gompert Z, Buerkle CA, Nachman MW and Tucker PK: The variable genomic architecture of isolation between hybridizing species of house mice. Evolution. 64:472–485. 2010. View Article : Google Scholar
23	Kobayashi F, Yamaguchi M and Mitsuhashi S: Drug resistance to aminoglycosidic antibiotics in Pseudomonas aeruginosa and its lability. Jpn J Microbiol. 16:425–431. 1972. View Article : Google Scholar : PubMed/NCBI
24	Yagisawa M, Yamamoto H, Naganawa H, Kondo S and Takeuchi T: A new enzyme in Escherichia coli carrying R-factor phosphorylating 3′-hydroxyl of butirosin A, kanamycin, neamine and ribostamycin. J Antibiot (Tokyo). 25:748–750. 1972. View Article : Google Scholar
25	Wang H and Gunsalus RP: The nrfA and nirB nitrite reductase operons in Escherichia coli are expressed differently in response to nitrate than to nitrite. J Bacteriol. 182:5813–5822. 2000. View Article : Google Scholar : PubMed/NCBI
26	Bowers LM, Lapoint K, Anthony L, Pluciennik A and Filutowicz M: Bacterial expression system with tightly regulated gene expression and plasmid copy number. Gene. 340:11–18. 2004. View Article : Google Scholar : PubMed/NCBI
27	Wu YC and Liu ST: A sequence that affects the copy number and stability of pSW200 and ColE1. J Bacteriol. 192:3654–3660. 2010. View Article : Google Scholar : PubMed/NCBI